Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tallac Therapeutics has raised $5.0M in total funding. The most recent round was Debt Financing. The last funding was announced in August 2023.
Tallac Therapeutics's investors include Matrix Partners China, venBio Partners, Lightstone Ventures, Horizon Technology Finance, MRL Ventures Fund.
Tallac Therapeutics is headquartered in Burlingame, United States.
Tallac Therapeutics offers next generation immunotherapies for cancer patients.
Tallac Therapeutics is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tallac Therapeutics — Funding & Investors." VCBacked, August 2, 2023, https://www.vcbacked.co/company/tallac-therapeutics. Accessed November 15, 2026.
VCBacked. (2023). Tallac Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/tallac-therapeutics
{{cite web |title=Tallac Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tallac-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Tallac Therapeutics? Request a listing update